AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33165312 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of participants from analyses
Number of subjects: 7
Study 33165312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of good control of incomplete outcome data
Number of subjects: 7
Study 33165312 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis by 'as treated'
Number of subjects: 7
Study 33165312 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis by 'per protocol'
Number of subjects: 7
Study 35842108 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 450
Study 35842108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with paroxetine or venlafaxine extended release
Number of subjects: 450
Study 35842108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PE and medication
Number of subjects: 450
Study 33382069 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMA-CD
Number of subjects: 57
Study 33382069 — intervention group
Group type: COMPARATOR
Intervention: SES-CD
Number of subjects: 57
Study 36299678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological integrated care protocols and standard care
Number of subjects: 116
Study 36299678 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 116
Study 35918624 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg every 8 hours (control group)
Number of subjects: 11
Study 35918624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg at breakfast and lunch, placebo at dinner (experimental group)
Number of subjects: 11
Study 33315111 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 10003
Study 33315111 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA with FFRCT
Number of subjects: 10003
Study 33315111 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 10003
Study 34669586 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural C-reactive protein (CRP) ≥2 mg/L
Number of subjects: 1800
Study 34669586 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural HbA1c ≥6% (42 mmol/mol)
Number of subjects: 1800
Study 34669586 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural creatinine clearance (CrCl) <60 ml/min
Number of subjects: 1800
Study 34669586 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-use of statins
Number of subjects: 1800
Study 34309111 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-oncologist discordance in patient's life expectancy estimates
Number of subjects: 0
Study 32854653 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrasound and contrast-enhanced ultrasound (CEUS) features for diagnosing HAE
Number of subjects: 120
Study 32854653 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified US scoring system for diagnosing HAE
Number of subjects: 120
Study 32854653 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound findings for HAE lesions
Number of subjects: 120
Study 32854653 — intervention group
Group type: COMPARATOR
Intervention: CEUS findings for HAE lesions
Number of subjects: 120
Study 35643520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ma’s bamboo‐based medicinal moxibustion therapy
Number of subjects: 312
Study 35643520 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 312
Study 32133778 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 24
Study 32133778 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 5 mg
Number of subjects: 24
Study 32133778 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine 2.5 mg + Pseudoephedrine 60 mg
Number of subjects: 24
Study 32133778 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 24
Study 32133778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 24
Study 32361019 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG
Number of subjects: 47
Study 32361019 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea
Number of subjects: 47
Study 32361019 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 47
Study 32361019 — intervention group
Group type: COMPARATOR
Intervention: Distilled Water
Number of subjects: 47
Study 35869772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HF group)
Number of subjects: 56
Study 35869772 — intervention group
Group type: COMPARATOR
Intervention: Conventional mask oxygen (M group)
Number of subjects: 56
Study 33358241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endopelvic fascia-preserving RALP
Number of subjects: 158
Study 33358241 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard operation)
Number of subjects: 158
Study 36472675 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment involving 10–12 sessions attended by the mother and an identified family member (father) at each session.
Number of subjects: 32
Study 33023579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen added to permethrin-treated bed nets
Number of subjects: 0
Study 33023579 — intervention group
Group type: COMPARATOR
Intervention: Permethrin-treated bed nets without pyriproxyfen
Number of subjects: 0
Study 34882193 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic treatment after periodontal stabilization
Number of subjects: 36
Study 34882193 — intervention group
Group type: COMPARATOR
Intervention: Periodontal maintenance only (control group)
Number of subjects: 36
Study 32311845 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 5 cmH2O
Number of subjects: 18
Study 32311845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CPAP with Sustained Inflation (SI; 15 seconds at 25 cmH2O after 5 seconds of CPAP)
Number of subjects: 18
Study 32311845 — intervention group
Group type: COMPARATOR
Intervention: Control group (CPAP only)
Number of subjects: 18
Study 36422809 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP16001 (2 mg) + Metformin (1000 mg bid for 7 days)
Number of subjects: 0
Study 36422809 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1000 mg bid for 7 days)
Number of subjects: 0
Study 33065133 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 1
Study 32100719 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous collagen injection (Group A, n = 10)
Number of subjects: 30
Study 32100719 — intervention group
Group type: EXPERIMENTAL
Intervention: Periradicular collagen injection (Group B, n = 10)
Number of subjects: 30
Study 32100719 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural collagen injection (Group C, n = 10)
Number of subjects: 30
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitosis Kinase Score (MKS) assessed at surgery
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitosis Kinase Score (MKS) before treatment
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitosis Kinase Score (MKS) in paired samples after treatment
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitosis Kinase Score (MKS) in ER+ patients
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitosis Kinase Score (MKS) in ER- patients
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: p21 expression at surgery
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: p21 expression in ER+ patients
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: p21 expression in ER- patients
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MKS and p21 expression
Number of subjects: 417
Study 616062701 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk groups based on MKS and p21
Number of subjects: 417
Study 35543888 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive preventive intervention (API)
Number of subjects: 0
Study 35543888 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 0
Study 32644148 — intervention group
Group type: EXPERIMENTAL
Intervention: Epimacular brachytherapy (EMB) plus as-needed ranibizumab
Number of subjects: 363
Study 32644148 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 363
Study 35171317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g meropenem, 3-h infusion
Number of subjects: 45
Study 35171317 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g meropenem, 3-h infusion
Number of subjects: 45
Study 35171317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g meropenem, 6-h infusion
Number of subjects: 45
Study 34641946 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 95
Study 32418546 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-OSU6162 treatment
Number of subjects: 30
Study 35589459 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid outlining the benefits and harms of shoulder surgery and non‐surgical options
Number of subjects: 425
Study 35589459 — intervention group
Group type: COMPARATOR
Intervention: General information about shoulder pain from the NHS
Number of subjects: 425
Study 33302116 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day elemental calcium
Number of subjects: 791
Study 33302116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 791
Study 35511770 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation group (O-arm image guidance system)
Number of subjects: 20
Study 35511770 — intervention group
Group type: COMPARATOR
Intervention: Traditional group
Number of subjects: 20
Study 35511770 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation group
Number of subjects: 20
Study 35511770 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation group and Traditional group
Number of subjects: 20
Study 36042056 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL + Sr-89
Number of subjects: 30
Study 36042056 — intervention group
Group type: COMPARATOR
Intervention: ZOL
Number of subjects: 30
Study 33035762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cocaine users (CCUs)
Number of subjects: 24
Study 33035762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use during the previous month
Number of subjects: 24
Study 33035762 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 24
Study 35817581 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised feedback on potentially inappropriate prescribing (PIP) of bronchodilator inhalers; feedback included visualised medication histories and action-oriented messages, sent in July 2015, February 2016, and August 2016.
Number of subjects: 233
Study 35817581 — intervention group
Group type: COMPARATOR
Intervention: Control group received feedback on an unrelated subject.
Number of subjects: 233
Study 35817581 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intervention vs control practices.
Number of subjects: 233
Study 33397667 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE intervention (6 weekly 1-hour sessions via videoconferencing)
Number of subjects: 75
Study 33397667 — intervention group
Group type: COMPARATOR
Intervention: Medication monitoring control group (electronic pill bottle and usual oncology care)
Number of subjects: 75
Study 33355251 — intervention group
Group type: EXPERIMENTAL
Intervention: Various implementation strategies
Number of subjects: 33
Study 33355251 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced learning approaches
Number of subjects: 33
Study 32636122 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 2030
Study 32636122 — intervention group
Group type: EXPERIMENTAL
Intervention: WHR
Number of subjects: 2030
Study 32443961 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based monitoring system for self-monitored blood glucose and blood pressure values
Number of subjects: 0
Study 32443961 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33548222 — intervention group
Group type: EXPERIMENTAL
Intervention: Button
Number of subjects: 12
Study 33548222 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip
Number of subjects: 12
Study 33548222 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 35779553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase (0.25 mg/kg to a maximum of 25 mg)
Number of subjects: 1600
Study 35779553 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg to a maximum of 90 mg; 0.09 mg/kg as a bolus and then a 60 min infusion of the remaining 0.81 mg/kg)
Number of subjects: 1600
Study 35779553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Number of subjects: 1600
Study 35779553 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1600
Study 34152102 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate practice debriefing
Number of subjects: 50
Study 34152102 — intervention group
Group type: COMPARATOR
Intervention: Standardized debriefing
Number of subjects: 50
Study 34871098 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg QD
Number of subjects: 79
Study 34871098 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 400 mg BID
Number of subjects: 79
Study 34871098 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg BID
Number of subjects: 79
Study 34871098 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 1200 mg QD
Number of subjects: 79
Study 34871098 — intervention group
Group type: COMPARATOR
Intervention: HRZE (isoniazid, rifampin, pyrazinamide, ethambutol)
Number of subjects: 79
Study 34871098 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg BID
Number of subjects: 79
Study 33641656 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-Inulin Co-supplementation
Number of subjects: 96
Study 33641656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 34508734 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure program
Number of subjects: 1005
Study 34508734 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure program (internalising personality traits)
Number of subjects: 1005
Study 34508734 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1005
Study 33320168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine once a day for 1 week, then once a week for 23 weeks
Number of subjects: 207
Study 33320168 — intervention group
Group type: COMPARATOR
Intervention: 0.01% atropine once a day for 6 months
Number of subjects: 207
Study 36228639 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice daily for 3 days and then 0.6 mg once daily for 25 days
Number of subjects: 3881
Study 36228639 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control for colchicine)
Number of subjects: 3881
Study 36228639 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily for 28 days
Number of subjects: 3881
Study 36228639 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control for aspirin)
Number of subjects: 3881
Study 36228639 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 3881
Study 36228639 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3881
Study 34628831 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral prednisone once a day for 14 days (Group A)
Number of subjects: 150
Study 34628831 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg oral prednisone once a day for 14 days (Group B)
Number of subjects: 150
Study 34628831 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral prednisone once a day for 14 days (Group C)
Number of subjects: 150
Study 34628831 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 150
Study 34628831 — intervention group
Group type: COMPARATOR
Intervention: Asthma patients in all groups
Number of subjects: 150
Study 35152882 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde appendicitis therapy (ERAT)
Number of subjects: 99
Study 35152882 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 99
Study 35152882 — intervention group
Group type: EXPERIMENTAL
Intervention: Open appendectomy (OA)
Number of subjects: 99
Study 35152882 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 99
Study 33410380 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSA‐CRIF (Percutaneous Distractor and Subtalar Arthroscopy Closed Reduction followed by Internal Fixation)
Number of subjects: 59
Study 34550915 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention
Number of subjects: 0
Study 34550915 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33478517 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojta specific tactile input (V-STI)
Number of subjects: 40
Study 33478517 — intervention group
Group type: COMPARATOR
Intervention: Non-specific tactile input (non-STI)
Number of subjects: 40
Study 35181556 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT)
Number of subjects: 60
Study 35181556 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 60
Study 35181556 — intervention group
Group type: EXPERIMENTAL
Intervention: GDFT and SC
Number of subjects: 60
Study 35181556 — intervention group
Group type: EXPERIMENTAL
Intervention: GDFT
Number of subjects: 60
Study 33676342 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological inflexibility
Number of subjects: 85
Study 33676342 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-related guilt (guilt cognitions, guilt distress, overall guilt)
Number of subjects: 85
Study 32014493 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (diet and/or exercise)
Number of subjects: 105
Study 36209196 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor intervention (self-painted humorous business card)
Number of subjects: 132
Study 36209196 — intervention group
Group type: COMPARATOR
Intervention: Standard breast examination
Number of subjects: 132
Study 34285165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9 µg HA/AS03B
Number of subjects: 185
Study 34285165 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 µg HA/AS03C
Number of subjects: 185
Study 34285165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9 µg HA/AS03C
Number of subjects: 185
Study 34285165 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 µg HA/AS03C
Number of subjects: 185
Study 34285165 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 µg HA/AS03D
Number of subjects: 185
Study 33927696 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise reduction of 12.5 IU rec-FSH daily in the Study group (SG)
Number of subjects: 108
Study 33927696 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with standard gonadotropin stimulation
Number of subjects: 108
Study 32470022 — intervention group
Group type: EXPERIMENTAL
Intervention: High H2 water (containing 7 ppm of H2: 3.5 mg H2 in 500-mL water)
Number of subjects: 68
Study 32470022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (molecular nitrogen (N2)‐containing water)
Number of subjects: 68
Study 34060416 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine paste, administered once weekly for eight consecutive weeks
Number of subjects: 80
Study 34060416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study 33291159 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clip closure after endoscopic mucosal resection (EMR)
Number of subjects: 458
Study 33291159 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with complete closure
Number of subjects: 458
Study 33037080 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib treatment
Number of subjects: 274
Study 615916148 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral supplement containing 10mg lutein, 2mg zeaxanthin and 10mg meso-zeaxanthin for a period of 6 months
Number of subjects: 88
Study 615916148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 35997261 — intervention group
Group type: EXPERIMENTAL
Intervention: First STEPS intervention (peer parent coaching, structured behavioral counseling, professional consultations)
Number of subjects: 157
Study 35997261 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 157
Study 35997261 — intervention group
Group type: EXPERIMENTAL
Intervention: First STEPS intervention and Usual care
Number of subjects: 157
Study 34750767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 34750767 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 80
Study 32605106 — intervention group
Group type: EXPERIMENTAL
Intervention: Run Interval Training (RIT), n = 9
Number of subjects: 19
Study 32605106 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON), n = 10
Number of subjects: 19
Study 35976361 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Medical Visits (GMVs)
Number of subjects: 152
Study 35976361 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 152
Study 33080376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA)
Number of subjects: 463
Study 33080376 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 463
Study 33080376 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA
Number of subjects: 463
Study 33080376 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 463
Study 32706780 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal‐Transcranial Direct Current Stimulation (A‐tDCS)
Number of subjects: 20
Study 32706780 — intervention group
Group type: COMPARATOR
Intervention: Sham A‐tDCS
Number of subjects: 20
Study 34775413 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 475